Can This News Push Ocugen Ahead of Pfizer and Moderna?
A year ago, Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were working on bringing their coronavirus vaccine candidates to market. Ocugen (NASDAQ: OCGN) was focusing on something completely different: gene therapy for eye diseases that cause blindness. No one expected this clinical-stage company to take part in the vaccine race.
Fast-forward to December: That's when Ocugen signed on to co-commercialize Bharat Biotech's coronavirus vaccine candidate in the U.S. Ocugen will keep 45% of any profit in the U.S. Since then, the shares have soared. And investors have watched Ocugen's every step. Right now, the latest step is a report about the vaccine candidate's performance against coronavirus variants of concern or interest. Can this help Ocugen eventually leap ahead of its bigger rivals? Let's take a closer look.
Image source: Getty Images.
Source Fool.com
